

British Health Professionals in Rheumatology (BHPR) Response to NICE ACD re Golimumab for the treatment of Rheumatoid Arthritis after failure of previous DMARD drugs

The British Health Professionals in Rheumatology (BHPR) welcome this opportunity to respond to the ACD re Golimumab for the treatment of Rheumatoid Arthritis after failure of previous DMARD drugs..

We note the ACD report and its findings and sympathise with the difficult challenges that the NICE appraisal committee constantly faces with undertaking economic modelling that only considers the short term costs and benefits of treatments.

We note the following:

Provisional recommendations:

BHPR noted the comment in 1.4 – the 100mg dosing regime is highly unlikely to be utilised in clinical practice.

The monthly dosing of Golimumab is particularly important as patients generally prefer a less frequent dosing schedule as it enables them to continue working and maintain their financial independence.